Sustained release docetaxel-incorporated lipid nanoparticles with improved pharmacokinetics for oral and parenteral administration

References

• Abdelbary G, Fahmy RH. Diazepam-loaded solid lipid nanoparticles: Design and characterization. AAPS PharmSciTech, 2009;10:211–9.
   PubMed Web of Science ®Google Scholar
• Almeida EDP, Costa AA, Serafini MR, Rossetti FC, Marchetti JM, Sarmento VHV, Nunes RS, Valerio MEG, Araújo AAS, Lira AAM. Preparation and characterization of chloroaluminum phthalocyanine-loaded solid lipid nanoparticles by thermal analysis and powder X-ray diffraction techniques. J Therm Anal Calorim, 2011;108:191–6.
   Web of Science ®Google Scholar
• Anton N, Benoit J-P, Saulnier P. Design and production of nanoparticles formulated from nano-emulsion templates—A review. J Control Release, 2008;128:185–99.
   PubMed Web of Science ®Google Scholar
• Choi JY, Thapa RK, Yong CS, Kim JO. Nanoparticle-based combination drug delivery systems for synergistic cancer treatment. J Pharm Investig, 2016;46:325–39.
   Google Scholar
• Constantinides PP. Lipid microemulsions for improving drug dissolution and oral absorption: Physical and biopharmaceutical aspects. Pharm Res, 1995;12:1561–72.
   PubMed Web of Science ®Google Scholar
• Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release, 2010;148:135–46.
   PubMed Web of Science ®Google Scholar
• Estella-Hermoso De Mendoza A, Rayo M, Mollinedo F, Blanco-Prieto MJ. Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: Development and in vitro characterization. Eur J Pharm Biopharm, 2008;68:207–13.
   PubMed Web of Science ®Google Scholar
• Fang G, Tang B, Chao Y, Zhang Y, Xu H, Tang X. Improved oral bioavailability of docetaxel by nanostructured lipid carriers: In vitro characteristics, in vivo evaluation and intestinal transport studies. RSC Adv, 2015;5:96437–47.
   Web of Science ®Google Scholar
• Gao K, Sun J, Liu K, Liu X, He Z. Preparation and characterization of a submicron lipid emulsion of docetaxel: submicron lipid emulsion of docetaxel. Drug Dev Ind Pharm, 2008;34:1227–37.
   PubMed Web of Science ®Google Scholar
• Harde H, Das M, Jain S. Solid lipid nanoparticles: An oral bioavailability enhancer vehicle. Expert Opin Drug Deliv, 2011;8:1407–24.
   PubMed Web of Science ®Google Scholar
• Hu K, Cao S, Hu F, Feng J. Enhanced oral bioavailability of docetaxel by lecithin nanoparticles: Preparation, in vitro, and in vivo evaluation. Int J Nanomedicine, 2012;7:3537–45.
   PubMed Web of Science ®Google Scholar
• Jain A, Thakur K, Kush P, Jain UK. Docetaxel loaded chitosan nanoparticles: Formulation, characterization and cytotoxicity studies. Int J Biol Macromol, 2014;69:546–53.
   PubMed Web of Science ®Google Scholar
• Jianping Q, Yi L, Wei W. Absorption, disposition and pharmacokinetics of solid lipid nanoparticles. Curr Drug Metab, 2012;13:418–28.
   PubMed Web of Science ®Google Scholar
• Joshi MD, Muller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm, 2009;71:161–72.
   PubMed Web of Science ®Google Scholar
• Jun YJ, Jadhav VB, Min JH, Cui JX, Chae SW, Choi JM, Kim I-S, Choi S-J, Lee HJ, Sohn YS. Stable and efficient delivery of docetaxel by micelle-encapsulation using a tripodal cyclotriphosphazene amphiphile. Int J Pharm, 2012;422:374–80.
   PubMed Web of Science ®Google Scholar
• Kalepu S, Manthina M, Padavala V. Oral lipid-based drug delivery systems – An overview. Acta Pharm Sin B, 2013;3:361–72.
   Web of Science ®Google Scholar
• Kanapathipillai M, Brock A, Ingber DE. Nanoparticle targeting of anti-cancer drugs that alter intracellular signaling or influence the tumor microenvironment. Adv Drug Deliv Rev, 2014;79-80:107–18.
   PubMed Web of Science ®Google Scholar
• Kim J-K, Yuan H, Nie J, Yang Y-T, Leggas M, Potter PM, Rinehart J, Jay M, Lu X. High payload dual therapeutic-imaging nanocarriers for triggered tumor delivery. Small, 2012;8:2895–903.
   PubMed Web of Science ®Google Scholar
• Kolate A, Baradia D, Patil S, Vhora I, Kore G, Misra A. PEG - A versatile conjugating ligand for drugs and drug delivery systems. J Control Release, 2014;192:67–81.
   PubMed Web of Science ®Google Scholar
• Koziara JM, Lockman PR, Allen DD, Mumper RJ. Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release, 2004;99:259–69.
   PubMed Web of Science ®Google Scholar
• Le Garrec D, Gori S, Karkan D, Luo L, Lessard DG, Smith D, Ranger M, Yessine MA, Leroux JC. Preparation, characterization, cytotoxicity and biodistribution of docetaxel-loaded polymeric micelle formulations. J Drug Deliv Sci Technol, 2005;15:115–20.
   Web of Science ®Google Scholar
• Lim S-J, Kim C-K. Formulation parameters determining the physicochemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid. Int J Pharm, 2002;243:135–46.
   PubMed Web of Science ®Google Scholar
• Liu D, Liu Z, Wang L, Zhang C, Zhang N. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerfaces, 2011;85:262–9.
   PubMed Web of Science ®Google Scholar
• Lu X, Howard MD, Talbert DR, Rinehart JJ, Potter PM, Jay M, Leggas M. Nanoparticles containing anti-inflammatory agents as chemotherapy adjuvants II: role of plasma esterases in drug release. AAPS J, 2009;11:120–2.
   PubMed Web of Science ®Google Scholar
• Luan J, Yang X, Chu L, Xi Y, Zhai G. PEGylated long circulating nanostructured lipid carriers for Amoitone B: Preparation, cytotoxicity and intracellular uptake. J Colloid Interface Sci, 2014;428:49–56.
   PubMed Web of Science ®Google Scholar
• Mehnert W, Mäder K. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev, 2001;47:165–96.
   PubMed Web of Science ®Google Scholar
• Mei L, Zhang Z, Zhao L, Huang L, Yang XL, Tang J, Feng SS. Pharmaceutical nanotechnology for oral delivery of anticancer drugs. Adv Drug Deliv Rev, 2013;65:880–90.
   PubMed Web of Science ®Google Scholar
• Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: Formulating poorly water-soluble compounds. Toxicol Pathol, 2008;36:43–8.
   PubMed Web of Science ®Google Scholar
• Mosallaei N, Jaafari MR, Hanafi-Bojd MY, Golmohammadzadeh S, Malaekeh-Nikouei B. Docetaxel-loaded solid lipid nanoparticles: Preparation, characterization, in vitro, and in vivo evaluations. J Pharm Sci, 2013;102:1994–2004.
   PubMed Web of Science ®Google Scholar
• Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – A review of the state of the art. Eur J Pharm Biopharm, 2000;50:161–77.
   PubMed Web of Science ®Google Scholar
• Naguib YW, Rodriguez BL, Li X, Hursting SD, Williams RO III, Cui Z. Solid lipid nanoparticle formulations of docetaxel prepared with high melting point triglycerides: In vitro and in vivo evaluation. Mol Pharm, 2014;11:1239–49.
   PubMed Web of Science ®Google Scholar
• Narvekar M, Xue HY, Eoh JY, Wong HL. Nanocarrier for poorly water-soluble anticancer drugs–barriers of translation and solutions. AAPS PharmSciTech, 2014;15:822–33.
   PubMed Web of Science ®Google Scholar
• Natarajan JV, Nugraha C, Ng XW, Venkatraman S. Sustained-release from nanocarriers: A review. J Control Release, 2014;193:122–38.
   PubMed Web of Science ®Google Scholar
• Park JY, Kim M-G, Shim G, Oh Y-K. Lipid-based antigen delivery systems. J Pharm Investig, 2016;46:295–304.
   Google Scholar
• Park O, Yu G, Jung H, Mok H. Recent studies on micro-/nano-sized biomaterials for cancer immunotherapy. J Pharm Investig, 2017;47:11–18.
   Google Scholar
• Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol, 2007;2:751–60.
   PubMed Web of Science ®Google Scholar
• Puri A, Loomis K, Smith B, Lee J-H, Yavlovich A, Heldman E, Blumenthal R. Lipid-based nanoparticles as pharmaceutical drug carriers: From concepts to clinic. Crit Rev Ther Drug Carrier Syst, 2009;26:523–80.
   PubMed Web of Science ®Google Scholar
• Qureshi OS, Zeb A, Akram M, Kim M-S, Kang J-H, Kim H-S, Majid A, Han I, Chang S-Y, Bae O-N, Kim J-K. Enhanced acute anti-inflammatory effects of CORM-2-loaded nanoparticles via sustained carbon monoxide delivery. Eur J Pharm Biopharm, 2016;108:187–95.
   PubMed Web of Science ®Google Scholar
• Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery. II. Drug incorporation and physicochemical characterization. J Microencapsul, 1999;16:205–13.
   PubMed Web of Science ®Google Scholar
• Seo YG, Kim DH, Ramasamy T, Kim JH, Marasini N, Oh YK, Kim DW, Kim JK, Yong CS, Kim JO, Choi HG. Development of docetaxel-loaded solid self-nanoemulsifying drug delivery system (SNEDDS) for enhanced chemotherapeutic effect. Int J Pharm, 2013;452:412–20.
   PubMed Web of Science ®Google Scholar
• Severino P, Andreani T, Macedo AS, Fangueiro JF, Santana MH, Silva AM, Souto EB. Current state-of-art and new trends on lipid nanoparticles (SLN and NLC) for oral drug delivery. J Drug Deliv, 2012;2012:750891.
   PubMedGoogle Scholar
• Silvia F, Eugenia N, Shyam B, Sharath H, Melissa L, Alessandro G. Docetaxel/2-hydroxypropyl β-cyclodextrin inclusion complex increases docetaxel solubility and release from a nanochannel drug delivery system. Curr Drug Targets, 2015;16:1645–9.
   PubMed Web of Science ®Google Scholar
• Sim T, Lim C, Hoang NH, Joo H, Lee JW, Kim D-W, Lee ES, Youn YS, Kim JO, Oh KT. Nanomedicines for oral administration based on diverse nanoplatform. J Pharm Investig, 2016;46:351–62.
   Google Scholar
• Singh SK, Banala VT, Gupta GK, Verma A, Shukla R, Pawar VK, Tripathi P, Mishra PR. Development of docetaxel nanocapsules for improving in vitro cytotoxicity and cellular uptake in MCF-7 cells. Drug Dev Ind Pharm, 2015;41:1759–68.
   PubMed Web of Science ®Google Scholar
• Üner M. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC): Their benefits as colloidal drug carrier systems. Pharmazie, 2006;61:375–86.
   PubMed Web of Science ®Google Scholar
• Üner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine, 2007;2:289–300.
   PubMed Web of Science ®Google Scholar
• Wissing S, Kayser O, Müller R. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev, 2004;56:1257–72.
   PubMed Web of Science ®Google Scholar
• Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev, 2007;59:491–504.
   PubMed Web of Science ®Google Scholar
• Yin YM, Cui FD, Mu CF, Choi MK, Kim JS, Chung SJ, Shim CK, Kim DD. Docetaxel microemulsion for enhanced oral bioavailability: Preparation and in vitro and in vivo evaluation. J Control Release, 2009;140:86–94.
   PubMed Web of Science ®Google Scholar
• Yousaf AM, Mustapha O, Kim DW, Kim DS, Kim KS, Jin SG, Yong CS, Youn YS, Oh YK, Kim JO, Choi HG. Novel electrosprayed nanospherules for enhanced aqueous solubility and oral bioavailability of poorly water-soluble fenofibrate. Int J Nanomedicine, 2016;11:213–21.
   PubMed Web of Science ®Google Scholar
• Yu MK, Park J, Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics, 2012;2:3–44.
   PubMed Web of Science ®Google Scholar
• Zeb A, Qureshi OS, Kim H-S, Cha J-H, Kim H-S, Kim J-K. Improved skin permeation of methotrexate via nanosized ultradeformable liposomes. Int J Nanomedicine, 2016;11:3813–24.
   PubMed Web of Science ®Google Scholar
• Zhang F, Chang M, Yu Y, Zhang Y, Liu G, Wei T, Zuo T, Guan Y, Lin G, Zhao Z. Preparation and evaluation of lipid emulsified docetaxel-loaded nanoparticles. J Pharm Pharmacol, 2015;67:1546–55.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang N. How nanotechnology can enhance docetaxel therapy. Int J Nanomedicine, 2013;8:2927–41.
   PubMed Web of Science ®Google Scholar
• Zhao P, Astruc D. Docetaxel nanotechnology in anticancer therapy. ChemMedChem, 2012;7:952–72.
   PubMed Web of Science ®Google Scholar
• Zur Mühlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm, 1998;45:149–55.
   PubMed Web of Science ®Google Scholar